MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Checkpoint Therapeutics Inc

Suletud

SektorTervishoid

4.04 0.25

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.99

Max

4.05

Põhinäitajad

By Trading Economics

Töötajad

23

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+31.19% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

9. mai 2025

Turustatistika

By TradingEconomics

Turukapital

205M

Eelmine avamishind

3.79

Eelmine sulgemishind

4.04

Uudiste sentiment

By Acuity

50%

50%

173 / 386 Pingereas Healthcare

Checkpoint Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. märts 2025, 10:23 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma

14. dets 2024, 00:24 UTC

Suurimad hinnamuutused turgudel

Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval

25. juuli 2024, 13:02 UTC

Suurimad hinnamuutused turgudel

Checkpoint Therapeutics Shares Rise After FDA Accepts Resubmission of Cosibelimab

10. märts 2025, 02:12 UTC

Omandamised, ülevõtmised, äriostud

Checkpoint Controlling Shareholder Fortress Has Agreed to Vote in Favor of Transaction >524715.BY

10. märts 2025, 02:12 UTC

Omandamised, ülevõtmised, äriostud

Sun Pharma, Checkpoint Transaction Expected to Complete in 2Q 2025 >524715.BY

10. märts 2025, 02:11 UTC

Omandamised, ülevõtmised, äriostud

Sun Pharma, Checkpoint, Fortress Biotech Enter Into Royalty Agreement >524715.BY

10. märts 2025, 02:11 UTC

Omandamised, ülevõtmised, äriostud

Checkpoint Shareholders Entitled to Receive Up to Additional $0.70 if Cosibelimab if Approved in EU Prior to Certain Deadlines >524715.BY

10. märts 2025, 02:10 UTC

Omandamised, ülevõtmised, äriostud

Checkpoint Shareholders to Receive Upfront Cash Payment of $4.10/Share, Contingent Value Right >524715.BY

10. märts 2025, 02:10 UTC

Omandamised, ülevõtmised, äriostud

Sun Pharma to Acquire Checkpoint Therapeutics >524715.BY CKPT

10. märts 2025, 02:06 UTC

Omandamised, ülevõtmised, äriostud

Sun Pharma To Acquire Checkpoint Therapeutics >524715.BY CKPT

Võrdlus sarnastega

Hinnamuutus

Checkpoint Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

31.19% tõus

12 kuu keskmine prognoos

Keskmine 5.3 USD  31.19%

Kõrge 7 USD

Madal 4.1 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Checkpoint Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

1

Osta

2

Hoia

0

Müü

Sentiment

By Acuity

173 / 386 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

$

Ettevõttest Checkpoint Therapeutics Inc

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.